Objective: The butorphanol-azaperone-medetomidine fixed-dose combination (BAM, respectively, 30-12-12 mg mL-1) with subsequent antagonism by naltrexone-atipamezole was evaluated for reversible immobilization of captive cheetahs (Acinonyx jubatus).
Study design: Prospective, clinical trial.
Animals: Twelve cheetahs (six males and six females, weighing 37-57 kg) housed in enclosures, were immobilized at Hoedspruit Endangered Species Centre in the Republic of South Africa.
Methods: BAM volume dose rate was 0.009-0.014 mL kg-1 (mean ± standard deviation 0.010 ± 0.001 mL kg-1). Total dose in all animals was 0.5 mL. The actual doses were as follows: butorphanol (0.29 ± 0.04 mg kg-1), azaperone (0.12 ± 0.01 mg kg-1) and medetomidine (0.12 ± 0.01 mg kg-1). Physiologic variables and quality of immobilization were recorded every 5 minutes beginning at 15-20 minutes after darting. Arterial blood samples were collected three times at 20, 30 and 40 minutes after darting from all animals for analysis of blood oxygenation and acid-base status.
Results: The inductions were calm and smooth and mean induction time was 4.0 ± 1.1 minutes. Heart rate (50 ± 9 beats minute-1) and respiratory frequency (20 ± 3 breaths minute-1) were stable throughout immobilization. The recovery time after reversing with naltrexone and atipamezole was 9.1 ± 3.6 minutes.
Conclusions: and clinical relevance BAM proved to be a reliable and cardiovascular stable drug combination for immobilization of cheetahs.
Keywords: Azaperone; BAM; butorphanol; cheetah; immobilisation; medetomidine.
Copyright © 2018 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. All rights reserved.